- Stanford University
- Stanford Hospital & Clinics
- Lucile Packard Children's Hospital
- VA Palo Alto
- Santa Clara Valley Medical Center
Stanford School of Medicine
LaneConnex
Lane Medical Library & Knowledge
Management Center
a division of IRT
Ask UsSHC Antibiogram: Gram Negative Rods (a)
-
SHC Antibiogram 2007
(printable PDF)
Percent Susceptible by Broth Microdilution
| PENICILLINS | CEPHEMS | LACTAMS | AMINOGLYC's | OTHERS | Urine Only | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. Tested | Ampi- cillin |
Pipera- cillin |
Amp/ Sulbactam | Pip/ Tazo- bactam |
Cefa- zolin |
Cefo- taxime |
Cefe- pime |
Aztreo- nam (c) |
Imi- penem (c) |
Mero- penem |
Genta- micin |
Tobra- mycin |
Amik- acin |
Cipro- floxacin |
Levo- floxacin |
Trimeth/ Sulfa- methox |
1ST GENER- ATION Ceph's [oral] |
Nitro- furantoin |
|
| Achromobacter xylosoxidans | 26 | - | - | - | 76% | - | - | 12% | 0% | 96% | 84% | 8% | 4% | 12% | 8% | 40% | 72% | - | - |
| Acinetobacter baumannii | 20 | - | - | 55% | - | - | - | 50% | - | 75% | 70% | 60% | 95% | 70% | 55% | 60% | 50% | - | - |
| Burkholderia cepacia (d,e) | 7 | Ceftazidime 100% | - | Minocycline 71% | - | 57% | - | - | - | - | - | 100% | - | - | |||||
| Citrobacter freundii | 45 | 22% | - | 56% | 89% | 2% | 71% | 100% | 80% | 100% | 98% | 98% | 98% | 100% | 87% | 89% | 80% | - | 89% |
| Citrobacter koseri | 28 | 0% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - | 80% |
| Enterobacter aerogenes | 57 | 5% | - | 40% | 80% | 11% | 74% | 100% | 79% | 98% | 100% | 98% | 95% | 100% | 97% | 97% | 97% | - | 5% |
| Enterobacter cloacae | 112 | 9% | - | 20% | 80% | 3% | 73% | 95% | 74% | 100% | 100% | 99% | 98% | 100% | 98% | 99% | 87% | - | 28% |
| Escherichia coli | 1387 | 53% | - | 60% | 98% | 88% | 91% | 98% | 96% | 100% | 100% | 88% | 88% | 100% | 76% | 77 % | 70% | 55% | 95% |
| Klebsiella oxytoca | 65 | 8% | - | 72% | 88% | 69% | 98% | 99% | 99% | 100% | 100% | 99% | 99% | 100% | 97% | 99% | 91% | - | 70% |
| Klebsiella pneumoniae | 295 | 0% | - | 80% | 96% | 90% | 94% | 98% | 96% | 100% | 100% | 98% | 97% | 98% | 93% | 94% | 84% | 100% | 19% |
| Morganella morganii | 28 | 0% | - | 11% | 100% | 0% | 100% | 100% | 100% | - | - | 86% | 96% | 100% | 86% | - | 78% | - | 0% |
| Proteus mirabilis | 108 | 78% | - | 91% | 100% | 93% | 100% | 99% | 99% | - | - | 93% | 94% | 99% | 85% | - | 79% | - | 0% |
| Proteus vulgaris (d) | 9 | 0% | - | 89% | 100% | 11% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - | 0% |
| Pseudomonas aeruginosa | 528(f) | - | - | - | 88% | - | - | 77% | 69% | 85% | 88% | 75% | 87% | 91% | 74% | 72% | - | - | - |
| Ps. aeruginosa CF mucoid (e) | 196(f) | - | 83% | Ticarcillin 76% | - | 84% | 70% | 75% | 82% | - | 88% | - | 70% | - | - | - | - | ||
| Ps. aeruginosa CF non-mucoid (e) | 132(f) | - | 60% | Ticarcillin 58% | - | 62% | 54% | 62% | 68% | - | 57% | - | 42% | - | - | - | - | ||
| Salmonella spp. (d,g) | 5 | 80% | - | - | - | Ceftriaxone 100% | - | - | - | - | - | - | - | 100% | - | 100% | - | - | |
| Serratia marcescens | 69 | 0% | - | 4% | 97% | 0% | 96% | 100% | 99% | 99% | 100% | 100% | 96% | 100% | 88% | 94% | 94% | - | - |
| Stenotrophomonas maltophilia | 72 | - | - | Ticarcillin/ Clavulanate 44% | - | Levofloxacin 76% | - | - | - | - | - | - | 97% | - | - | ||||
| Cost | $ | $$$ | $$ | $$$ | $ | $$ | $$ | $$$ | $$$ | $$$ | $ | $ | $$ | $$ | $$ | $ | $ | $ | |
(a) Until final identifications are available, reports describe gram negative rods as lactose-fermenters (LF; such as
E.coli, K lebsiella, Enterobacter, Citrobacter); non-lactose fermenters (NLF, such as Proteus, Serratia, Salmonella,
Shigella), or non-fermenters (NF, such as Pseudomonas, Acinetobacter, Stenotrophomonas, and others, most of which are
intrinsically more resistant to many antibiotics).
(b) Not all isolates tested against every antibiotic listed.
(d) Data from isolate totals < 10 may be statistically unreliable.
(c) Unlike aztreonam, aminoglycosides have synergistic activity with b-lactams (ex: piperacillin, ampicillin) against
aerobic gram negative rods and enterococci. Aztreonam should only be used for treating documented infections due to
susceptible organisms in patients with anaphylactic reactions to b-lactams. In patients with renal insufficiency,
aminoglycosides can be administered safely when doses are adjusted for patient's renal function. For information on dosing,
including single daily dosing, please contact a Clinical Pharmacist (beeper # available from unit secretary).
(f) Pseudomonas aeruginosa isolates not corrected for duplicates.
(e) Cystic fibrosis patient isolates tested by disk diffusion.
(g) Infectious Diseases consultation strongly recommended for determining treatment of Salmonella sp. recovered from
blood.